drugset
drugset / Trial / NCT04379869

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

NCT04379869 ↗

Phase 1 Completed 28 enrolled Neuren Pharmaceuticals Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of NNZ-2591 when administered to healthy volunteers.

Timeline

Start
2020-05-29
Primary completion
2021-02-11
Completion
2021-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NNZ-2591 Small molecule — Oral

Indications

No indication recorded.